Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of Candin Challenge with Tofacitinib in Healthy Volunteers
NCT04985955Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candida albicans antigen (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Presence and Size of Induration in Active Versus Control at the Candin Injection Site at Day 5. Started Jul 2021; status: completed.
02
Drugs
candida albicans antigen
Beyond the preview
Go deeper on NCT04985955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985955.